U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H16N6O.ClH.H2O
Molecular Weight 374.825
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZONIPORIDE HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.NC(=N)NC(=O)C1=C(C2CC2)N(N=C1)C3=CC=CC4=NC=CC=C34

InChI

InChIKey=UCIJUEGJEFJRMP-UHFFFAOYSA-N
InChI=1S/C17H16N6O.ClH.H2O/c18-17(19)22-16(24)12-9-21-23(15(12)10-6-7-10)14-5-1-4-13-11(14)3-2-8-20-13;;/h1-5,8-10H,6-7H2,(H4,18,19,22,24);1H;1H2

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C17H16N6O
Molecular Weight 320.3485
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11259552 http://www.abcam.com/zoniporide-hydrochloride-ab142012.html

Zoniporide hydrochloride is a novel, potent and selective NHE-1 inhibitor (IC50 = 14 nM). Reduces infarct size in the isolated heart (EC50 = 0.25 nM). Attenuates post-ischemic cardiac contractile dysfunction and ischemia-reperfusion-induced ventricular fibrillation in vivo. Zoniporide hydrochloride represents a novel class of potent and selective human NHE-1 inhibitors with potential utility for providing cardioprotection in a clinical setting.

Originator

Pfizer
420
Curator's Comment: # Pfizer

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 12000.0 nM [IC50]
Inhibitor
8297
 14.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.07 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11277524
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZONIPORIDE plasma
Rattus norvegicus
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.5 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11277524
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZONIPORIDE plasma
Rattus norvegicus
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
46%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11277524
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZONIPORIDE plasma
Rattus norvegicus
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Disc. AE: Hepatic failure, Bilirubin elevated...
Other AEs: Headache, Atrial fibrillation...
AEs leading to
discontinuation/dose reduction:
Hepatic failure (0.8%)
Bilirubin elevated
Vomiting (25.6%)
Other AEs:
Headache (6.4%)
Atrial fibrillation (6.4%)
Tachycardia (10.9%)
Jaundice (2.3%)
Nausea (41.7%)
Elevated liver enzyme levels
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
AEs

AEs

AESignificanceDosePopulation
Elevated liver enzyme levels
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Hepatic failure 0.8%
Disc. AE
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Tachycardia 10.9%
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Jaundice 2.3%
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Vomiting 25.6%
Disc. AE
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Nausea 41.7%
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Atrial fibrillation 6.4%
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Headache 6.4%
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Bilirubin elevated Disc. AE
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
unhealthy, ADULT
n = 266
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 266
Sources:
https://pubmed.ncbi.nlm.nih.gov/16202888
Page: p.573
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1537

AO
16
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP3A4
1925
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
1537
 no
AO
16
 yes [Km 3.4 uM]
PubMed

PubMed

TitleDatePubMed
Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1).
2003 Spring
Basolateral Na+-H+ exchanger-1 in rat taste receptor cells is involved in neural adaptation to acidic stimuli.
2004 Apr 1
Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+/H+ exchanger isoform 1, in an experimental model of cardiopulmonary bypass.
2004 May
Initial rate analysis of zoniporide hydrolysis degradants using high-performance liquid chromatography coupled with mass spectrometric detection.
2007
Solute diffusion through stripped mouse duodenum.
2007 Dec
Zoniporide preserves left ventricular compliance during ventricular fibrillation and minimizes postresuscitation myocardial dysfunction through benefits on energy metabolism.
2007 Oct
Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach?
2008 Apr
Na+/H+ exchanger-1 inhibitors reduce neuronal excitability and alter na+ channel inactivation properties in rat primary sensory neurons.
2008 Jun
Paradoxical resistance to myocardial ischemia and age-related cardiomyopathy in NHE1 transgenic mice: a role for ER stress?
2009 Feb
Effects of KR-33028, a novel Na+/H+ exchanger-1 inhibitor, on glutamate-induced neuronal cell death and ischemia-induced cerebral infarct.
2009 Jan 12
Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences.
2010 Apr
In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.
2010 Aug
Role of the spinal Na+/H+ exchanger in formalin-induced nociception.
2011 Aug 21
Critical role of the STAT3 pathway in the cardioprotective efficacy of zoniporide in a model of myocardial preservation - the rat isolated working heart.
2011 Feb
Patents

Patents

06441176
6
06492401
7
06627643
6
06753334
6
06974813
6
JP2003510331A
14
WO2005079803A1
6

Sample Use Guides

In Vivo Use Guide
Rabbits: 0.25, 1, and 4 mg/kg/h, i.v.
Route of Administration: Intravenous
In Vitro Use Guide
Zoniporide inhibited 22Na(+) uptake in fibroblasts expressing human NHE-1 in a concentration-dependent manner (IC(50) = 14 nM)
Substance Class Chemical
Created
by admin
on Sat Dec 16 00:02:13 GMT 2023
Edited
by admin
on Sat Dec 16 00:02:13 GMT 2023
Record UNII
70297XU9ZO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZONIPORIDE HYDROCHLORIDE MONOHYDRATE
Common Name English
1H-PYRAZOLE-4-CARBOXAMIDE, N-(AMINOIMINOMETHYL)-5-CYCLOPROPYL-1-(5-QUINOLINYL)-, HYDROCHLORIDE, HYDRATE (1:1:1)
Systematic Name English
ZONIPORIDE MONOHYDROCHLORIDE MONOHYDRATE
Common Name English
Code System Code Type Description
PUBCHEM
22267662
Created by admin on Sat Dec 16 00:02:13 GMT 2023 , Edited by admin on Sat Dec 16 00:02:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID80235499
Created by admin on Sat Dec 16 00:02:13 GMT 2023 , Edited by admin on Sat Dec 16 00:02:13 GMT 2023
PRIMARY
FDA UNII
70297XU9ZO
Created by admin on Sat Dec 16 00:02:13 GMT 2023 , Edited by admin on Sat Dec 16 00:02:13 GMT 2023
PRIMARY
CAS
863406-85-3
Created by admin on Sat Dec 16 00:02:13 GMT 2023 , Edited by admin on Sat Dec 16 00:02:13 GMT 2023
PRIMARY
Related Record Type Details
Structure of ZONIPORIDE
PARENT -> SALT/SOLVATE
Structure of ZONIPORIDE HYDROCHLORIDE
ANHYDROUS->SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966